Immune reconstitution inflammatory syndrome: Emergence of a unique syndrome during highly active antiretroviral therapy

Medicine

Volumn 81, Issue 3, 2002, Pages 213-227

  Shelburne III, Samuel A ^a   Hamill, Richard J ^a   Rodriguez Barradas, Maria C ^a   Greenberg, Stephen B ^a   Atmar, Robert L ^a   Musher, Daniel M ^a   Gathe Jr , Joseph C ^a   Visnegarwala, Fehmida ^a   Trautner, Barbara W ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; COTRIMOXAZOLE; DEXAMETHASONE; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; ETHAMBUTOL; GANCICLOVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PREDNISONE; PROTEINASE INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; STEROID; THALIDOMIDE; UNINDEXED DRUG; VALACICLOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DRUG INDUCED DISEASE; FEMALE; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFLAMMATORY DISEASE; KAPOSI SARCOMA; MALE; MYCOBACTERIOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUTOIMMUNE DISEASES; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; SYNDROME;

EID: 0036251741     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200205000-00005     Document Type: Article

References (147)

1. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: Secondary prophylaxis
2. Paradoxical enlargement or development of intracranial tuberculomas during therapy: Case report and review
3. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy
4. Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy
5. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy
6. Restoration of the immune system with antiretroviral therapy
7. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis in advanced HIV disease
8. Mycobacterium avium complex causing endobronchial disease in AIDS patients after partial immune restoration
9. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection
10. HIV combination therapy: Immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy
11. Sarcoidosis in a patient with acquired immunodeficiency syndrome treated with interleukin-2
12. Sarcoidosis and HIV infection: Influence of highly active antiretroviral therapy
13. Granulomatous Pneumocystis carinii pneumonia in three patients with the acquired immune deficiency syndrome
14. Granulomatous pulmonary lesions in patients with the acquired immmunodeficiency syndrome (AIDS) and Pneumocystis carinii infection
15. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma
16. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome
17. Deterioration of disseminated cutaneous Mycobacterium avium complex infection with a leukemoid reaction following institution of highly active antiretroviral therapy
18. Herpes zoster and human immunodeficiency virus infection
19. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
20. Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy
21. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide
22. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
23. Sudden enlargement of a deep cervical lymph node during and after treatment for pulmonary tuberculosis
24. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-1999. A 37-year-old man with fever and diffuse lymphadenopathy
25. CMV retinitis in the era of HAART
26. Immunorestitution disease involving the innate and adaptive response
27. Paradoxical reactions in HIV and pulmonary TB
28. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents
29. Contrast enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients
30. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response
31. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy
32. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral-induced increases in CD4+ cell count
33. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy
34. Mycobacterial cutaneous manifestations: A new sign of immune restoration syndrome in patients with acquired immunodeficiency syndrome
35. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS associated progressive multifocal leukoencephalopathy
36. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy
37. Hepatitis C virus and human immunodeficiency virus: Clinical issues in coinfection
38. Highly active antiretroviral therapy
39. Adjunctive corticosteroid therapy for tuberculosis: A critical reappraisal of the literature
40. Changes in thymic function with age and during the treatment of HIV infection
41. Mycobacterium avium complex lymph node abscess after use of highly active antiretroviral therapy in a patient with AIDS
42. Management of elevated intracranial pressure in patients with cryptococcal meningitis
43. Pulmonary tuberculosis in AIDS patients: Transient chest radiographic worsening after initiation of antiretroviral therapy
44. Pneumocystis carinii pneumonia with an atypical granulomatous response
45. Immunopathology as a result of highly active antiretroviral therapy in HIV-1 infected patients
46. Antiretroviral therapy immune restoration disease in HIV-infected patients on HAART
47. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients
48. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis
49. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind placebo controlled trial
50. Pneumocystis carinii infection in the acquired immune deficiency syndrome
51. Anterior segment involvement in HIV-associated eye disease after the commencement of highly active antiretroviral therapy (HAART)
52. 6 cells/L following combination antiretroviral therapy including protease inhibitors
53. Delayed occurrence of Graves' disease after immune restoration with HAART
54. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection
55. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: Effects on cerebrospinal fluid markers of JC virus replication and immune response
56. Sarcoidosis after antiretroviral therapy in a patient with acquired immunodeficiency syndrome
57. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells
58. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience
59. Diagnosis and treatment of increased intracranial pressure in patients with AIDS and cryptococcal meningitis
60. Newly diagnosed pulmonary sarcoidosis in HIV-infected patients
61. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects
62. Immune recovery uveitis
63. CNS manifestations of paradoxical reaction in HIV+ TB patients on HAART
64. Assessment of type-1 and type-2 cytokines in HIV type-1 infected individuals: Impact of highly active antiretroviral therapy
65. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
66. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
67. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy
68. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy
69. Thyroid autoimmunity (Graves' disease) after immune restoration in HIV-infected patients receiving HAART
70. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients
71. Mycobacteria avium intracellulare (MAIS) reversal syndrome set off by highly active antiretroviral therapy (HAART). Improved immunity is not always good but it is better than no immunity
72. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: A new syndrome
73. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy
74. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis
75. Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy
76. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
77. Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects
78. Cavitating and noncavitating granulomas in AIDS patients with Pneumocystis pneumonitis
79. Loss of cytomegalovirusspecific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis
80. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
81. Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+ T-cell repopulation kinetics during highly active antiretroviral therapy
82. Enhancing progressive multifocal leukoencephalopathy: An indicator of improved immune status?
83. Immune mediated 'HAART' attack during treatment for tuberculosis
84. Immune recovery uveitis
85. Mediastinal lymphadenitis due to cryptococcal infection in HIV-positive patients on highly active antiretroviral therapy
86. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy
87. Immune restoration and CD4+ T-cell function with antiretroviral therapies
88. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS clinical trials group protocol 315
89. Recurrent pulmonary sarcoidosis in HIV-infected patients receiving highly active antiretroviral therapy
90. Long lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
91. Sarcoidosis complicated by HIV infection: Three case reports and a review of the literature
92. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations of CD4 T-cells in response to highly active anti-retroviral therapy
93. The changing face of AIDS-related opportunism: Cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review
94. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy
95. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors
96. Acute clinical hepatitis B in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy
97. Placebo-controlled trial of prednisone in advanced HIV-1 infection
98. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy
99. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection
100. Long term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease
101. Occurrence of Pneumocystis carinii pneumonia in HIV-1 infected patients responding to HAART: Is prophylaxis discontinuation a safe tool?
102. Opportunistic infections occurring during highly active antiretroviral treatment
103. Immune reconstitution CMV pneumonitis
104. Sarcoidosis in a patient with AIDS: A manifestation of the immune restoration syndrome
105. HIV protease inhibitors: Immunological insights
106. Normalization of anti-cryptococcal activity and interleukin-12 production after highly active antiretroviral therapy
107. Arthralgias and cryoglobulinemia during protease inhibitor therapy in a patient with human immunodeficiency virus and hepatitis C virus
108. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS)
109. Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy
110. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
111. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy
112. Immune reconstitution after 2 years of successful potent anti-retroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults
113. Paradoxical tuberculous reactions in HIV-infected patients
114. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents
115. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
116. Immunorestitution disease in relation to infection with Mycobacterium avium complex and leprosy
117. Localized mycobacterial immune reconstitution syndrome (LMIRS): Long term outcome and discontinuation of mycobacterial therapy
118. Mycobacterial lymphadenitis with the initiation of combination antiretroviral therapy
119. Mycobacterial lymphadenitis: Can highly active antiretroviral therapy (HAART) unmask subclinical infection?
120. Neovascularization of the optic disc after highly active antiretroviral therapy in an AIDS patient with cytomegalovirus retinitis. A new immune recovery-related ocular disorder?
121. Recovery of the immune system with antiretroviral therapy. The end of opportunism?
122. MHC haplotypes affect the expression of opportunistic infections in HIV patients
123. Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy
124. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment
125. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
126. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy
127. Immunerecovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy
128. Further observations of tuberculin reactions in active tuberculosis
129. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
130. Practice guidelines for the management of cryptococcal disease
131. Optic nerve head neovascularization in a patient with inactive cytomegalovirus retinitis and immune recovery
132. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998
133. Human immunodeficiency virus-associated polymyositis during immune restoration with combination antiretroviral therapy
134. Effect of HAART on natural history of AIDS-related opportunistic disorders
135. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy
136. Immune function and phenotype before and after highly active antiretroviral therapy
137. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy
138. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen
139. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient
140. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy
141. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient
142. HAART in HIV-infected patients: Restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viremia
143. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
144. HIV combination therapy: Partial immune restitution unmasking latent cryptococcal infection
145. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis
146. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects
147. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus infected patient receiving triple antiretroviral therapy